Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advinus Therapeutics and P2D Bioscience have signed a research and development collaboration for Attention Deficit Hyperactivity Disorder (ADHD).
Subscribe to our email newsletter
The collaboration aims at developing new class of ADHD treatments which demonstrate increased efficacy due to higher affinity for the target receptor, in addition to improved safety due to enhanced selectivity.
Advinus CEO and MD Dr. Rashmi Barbhaiya said academic institutions and their spinoff biotech companies are beginning to play an increasingly important role in discovering innovative drug candidates.
"The P2D ADHD program is a classical example of value Advinus provides to such institutions and benefits it derives from such collaborations," Barbhaiya added.
P2D Bioscience CEO and chairman Frank Zemlan said Advinus was identified by Indian-based team as the premier pre-clinical and early-stage clinical development company in southeast Asia.
"P2D partnered with Advinus because of their drug development expertise and experience," Zemlan added.
ADHD is the most commonly diagnosed psychiatric disorder in children, with symptoms continuing into adulthood in up to 50% of cases.